SubsidieMeestersTowArd demoCRatization Of ev-BAsed Therapies
EVerZom aims to revolutionize EV manufacturing with a patented scalable process, targeting GMP compliance and commercial production to lead the European market in clinical applications.
Projectdetails
Introduction
EVerZom has developed a patented, fast, cost-effective, large-scale standardized extracellular vesicles (EV) production process to address the manufacturing issues that hamper EV translation towards the clinic.
Achievements
EVerZom has performed a successful platform scale-up to 6L, meeting quantities needed for phase I trials, placing it at least 2 years ahead of known competitors.
Market Opportunity
With numerous European biotechs poised to enter clinical phase, it’s timely to provide industrial players with EV large-scale capabilities.
Future Goals
Hence, EVerZom intends to achieve key milestones during the next 2 years, including:
- Validation of platform GMP compliance at clinical phase I scale.
- Scale-up toward late-stage and commercial batch production.
- Platform expansion usefulness towards different cell lines.
Project Impact
The ACROBAT project will enable us to be aligned with the industrial players' roadmap, generate early revenues, and achieve our ambition to be a European pioneer and leader in the EV manufacturing market.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.700.000 |
| Totale projectbegroting | € 2.487.651 |
Tijdlijn
| Startdatum | 1-5-2022 |
| Einddatum | 30-4-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- EVERZOMpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process controlThe SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors. | EIC Pathfinder | € 1.364.281 | 2022 | Details |
Development of a marketable adjuvant candidate for vaccine applicationsADJUVACCINE aims to validate a synthetic platform for scalable production of optimized saponin adjuvants to enhance cost-effective vaccines and attract investment for market entry. | ERC POC | € 150.000 | 2023 | Details |
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac RepairTOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization. | ERC POC | € 150.000 | 2023 | Details |
High-Throughput Production of Extracellular Vesicles from Organoids under Rotating MotionThe project aims to develop a streamlined system for high-throughput production of extracellular vesicles (EVs) by integrating controlled cell configurations to enhance therapeutic potential. | ERC POC | € 150.000 | 2024 | Details |
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process control
The SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors.
Development of a marketable adjuvant candidate for vaccine applications
ADJUVACCINE aims to validate a synthetic platform for scalable production of optimized saponin adjuvants to enhance cost-effective vaccines and attract investment for market entry.
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac Repair
TOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization.
High-Throughput Production of Extracellular Vesicles from Organoids under Rotating Motion
The project aims to develop a streamlined system for high-throughput production of extracellular vesicles (EVs) by integrating controlled cell configurations to enhance therapeutic potential.